Search

News Cariprazine −⁠ a Cardiometabolically Friendly Antipsychotic

Part of the 63rd Czech-Slovak Psychopharmacological Conference, held online from January 15−16, 2021, featured a lecture by Prof. MUDr. Jiří Masopust, Ph.D., from the Psychiatric Clinic of the Faculty of Medicine, Charles University and University Hospital Hradec Králové, titled “Cariprazine: a Cardiometabolically Friendly Antipsychotic”.

Source: Schizophrenia and Antipsychotics 23. 2. 2021

News Anxiety Disorders and Autoimmune Thyroiditis –⁠ A Connection Rather Than Coincidence?

Anxiolytics commonly target the central nervous system. Newly published research by Ukrainian authors offers a different perspective –⁠ according to their findings, anxiety may be related to thyroid inflammation.

Source: Depression and Anxiety 29. 10. 2020

News Eletriptan and Its Role in Acute Migraine Therapy

In the acute treatment of moderate to severe migraine attacks, medications from the triptan group are primarily used. The following article summarizes important findings about eletriptan and its key results in clinical studies.

Source: Treatment of Severe Migraine 10. 5. 2022

News High-Dose Cyclophosphamide in Hard-to-Treat Patients with B-NHL

For hard-to-treat patients with non-Hodgkin lymphoma, cyclophosphamide administered in one or two cycles can help bridge the period needed to obtain other effective treatments, as inferred from the work of French authors recently published in the European Journal of Haematology.

Source: Non-Hodgkin Lymphomas and CLL 23. 4. 2020

Články časopisu

Author of the article: Aneta Sadílková, Kristýna Čmerdová Source: Časopis lékařů českých | 3-4/2022 12. 9. 2022

News How to vaccinate children against pneumococcus?

Pneumococcus is a dreaded pathogen causing serious diseases in pediatric patients. However, it can be effectively prevented with commonly available vaccines. Let's look at the updated recommendation of the Czech Vaccinological Society ČLS JEP from April this year.

Source: Regular Vaccination 30. 5. 2024

News Possibilities of Cannabis Use in Tourette Syndrome Therapy

A retrospective analysis and online survey conducted at a psychiatric clinic in Hanover, Germany, investigated the effectiveness and safety of using cannabis products in patients with Tourette syndrome in real-world practice.

Source: Medical Cannabis 20. 6. 2024

News Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention

Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or CV disease fail to reach target LDL-c levels even when given the maximum tolerated dose of conventional hypolipidemic treatment. For these patients, inclisiran—a small interfering RNA (siRNA) that lowers cholesterol—offers hope. In the following article, we present a model example of a patient after an acute coronary event for whom starting inclisiran treatment is appropriate.

Source: Chronic Heart Failure and Lipidology 23. 12. 2022

News Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin

Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.

Source: Diabetes 19. 4. 2022

News Bimekizumab in the treatment of moderate to severe hidradenitis suppurativa –⁠ another approved indication for this biological agent

In May, the primary results of the BE HEARD I and II studies evaluating the efficacy and safety of the IL-17A and IL-17F inhibitor bimekizumab in the treatment of moderate to severe hidradenitis suppurativa (HS) in adults were published in The Lancet. This is the first publication of the results of these Phase III studies. Based on these findings, the European Medicines Agency (EMA) approved bimekizumab (which is currently approved for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis) for the treatment of HS in adults who have not responded adequately to conventional systemic therapy.

Source: Psoriasis 1. 7. 2024

News Long-term Benefit of Luspatercept Therapy –⁠ Fresh Data from the MEDALIST Study

The goal of therapy for low-risk myelodysplastic syndrome (MDS) is to compensate for anemia, improve or maintain quality of life, and prolong the time to progression to higher-risk MDS (HR-MDS) or acute myeloid leukemia (AML). To manage anemia, we can resort to transfusion therapy or administer epoetins, lenalidomide, or luspatercept, the first representative of a class of drugs that support erythrocyte maturation. Last year's data from the follow-up of patients enrolled in the MEDALIST study pertain specifically to the latter.

Source: Myelodysplastic Syndrome (MDS) 22. 4. 2024

News The Link Between Various Sleep Disorders and the Onset of Depression: What Findings Did the Population Study in Denmark Bring?

A Danish population study published in June 2019 examined the link between different types of sleep disorders and the risk of developing depression. Which disorders confirmed this link after evaluating data from tens of thousands of patients?

Source: Depression and Anxiety 17. 3. 2020

News Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome

A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.

Source: Myelodysplastic Syndrome (MDS) 24. 5. 2024

News Treatment of Motor Symptoms of Parkinson's Disease

Parkinson's disease (PD) is one of the few neurodegenerative disorders for which effective symptomatic treatment is available. Unfortunately, causal or even neuroprotective therapy with proven efficacy does not yet exist, but properly chosen symptomatic therapy can positively influence the motor manifestations of the disease and significantly improve the patient's quality of life.

Source: Parkinson's Disease 12. 5. 2021

News Recent findings on the role and potential of L. reuteri in the therapy of GIT diseases

Probiotics contain bacterial or yeast strains similar to beneficial types naturally occurring in the human gastrointestinal tract. Their role in the therapy of gastrointestinal diseases has been extensively researched, demonstrating significant effects on a number of nosological units. One modality of probiotic therapy involves the administration of the bacteria L. reuteri, specifically the laboratory-modified strain DSM 17938.

Source: GI, colic and microbiome 20. 10. 2022